You want to charge $1M for that gene therapy? Here’s where you’re wrong
Spark Therapeutics $ONCE doesn’t have a green light yet from the FDA to sell its gene therapy for one small group of patients with a genetic flaw that causes inherited blindness. And company execs haven’t told anyone exactly what its wholesale price will be for voretigene neparvovec.
But the odds look great for this treatment to quickly nab the first approval for a vector-delivered gene therapy in the US — and it’s game on for a pricing debate that starts with an auction forecast of $1 million per treatment.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.